Search | Clinical Trials Finder

Conditions: Colitis Ulcerative, Ulcerative Colitis
Interventions: MK-8690, Placebo; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Anaheim, California • Coronado, California • Colorado Springs, Colorado + 8 more

Conditions: Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions: Octreotide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Overactive Bladder
Interventions: onabotulinumtoxinA, normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, oral placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 632 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 40
States / cities: Tucson, Arizona • Chula Vista, California • Long Beach, California + 34 more

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, Methotrexate, Placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: SARS-CoV Infection, Covid19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination); Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 12 Years and older
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more

Conditions: Ankylosing Spondylitis
Interventions: Secukinumab (75 mg), Secukinumab (150 mg), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 10
States / cities: Boise, Idaho • Cedar Rapids, Iowa • Portland, Oregon + 7 more

Conditions: Painful Intermetatarsal Neuroma (Morton's Neuroma)
Interventions: CNTX-4975, Placebo; Drug · Other
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Castro Valley, California + 10 more

Conditions: Hepatocellular Carcinoma
Interventions: Durvalumab, Bevacizumab, Placebo, Transarterial Chemoembolization (TACE); Drug · Other · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 24
States / cities: Costa Mesa, California • La Jolla, California • Orange, California + 19 more

Conditions: Healthy Volunteers
Interventions: ABBV-243, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Myofascial Pain Syndromes, Myofascial Trigger Point Pain, Trigger Point Pain, Myofascial
Interventions: OnabotulinumtoxinA, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Cleveland, Ohio • Mayfield Heights, Ohio • Westlake, Ohio

Conditions: Hypogonadism
Interventions: Acyline, Placebo Gel, Placebo Tablet, Testosterone Gel, Arimidex; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Preterm Birth
Interventions: 17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement, 17 alpha-hydroxy progesterone caproate and Placebo supplement; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 9 more

Conditions: Healthy Volunteer
Interventions: Subcutaneous RB006 0.5 mg/kg, Subcutaneous RB006 1.0 mg/kg, Subcutaneous RB006 3.0 mg/kg, Subcutaneous RB006 2.0 mg, Placebo; Drug
Lead sponsor: Regado Biosciences, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Systemic Lupus Erthematosus, Sjogren's Syndrome
Interventions: Omalizumab; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
Interventions: pamidronate, saline; Drug · Other
Lead sponsor: University of New Mexico; Other
Eligibility: 4 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Episodic Migraine
Interventions: BOTOX, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 775 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 82
States / cities: Hoover, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: APG777, Placebo; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: La Jolla, California • Long Beach, California • San Jose, California + 6 more

Conditions: Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions: Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna; Drug
Lead sponsor: Edgar LeClaire, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Wichita, Kansas

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections, Monthly placebo infusions + 3 times per week placebo injections; Biological · Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
Interventions: Bevacizumab, Placebo (Saline); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Postmenopausal Osteoporosis
Interventions: AGA2118, Placebo; Drug · Other
Lead sponsor: Angitia Biopharmaceuticals; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Gainesville, Georgia • Albuquerque, New Mexico + 2 more

Conditions: HIV
Interventions: Teduglutide, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Octreotide in Severe Polycystic Liver Disease

Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis

A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.

Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain

Cardiovascular Outcomes of Low Testosterone

Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD

Omalizumab for Lupus

Prevention of Post Operative Bone Loss in Children

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

T-regulatory Cells in ALS

Intranasal Bevacizumab for HHT-Related Epistaxis

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV